Bayer’s CEO said on Friday that the healthcare and crop chemicals group continues to firmly back its glyphosate weedkiller even after a recent courtroom loss in U.S. litigation over an alleged carcinogenic effect.
Moderna fell as much as 7% on Friday after Wall Street analysts raised concerns over faster declines in the efficacy of its experimental respiratory syncytial virus (RSV) vaccine when compared with rival shots from GSK and Pfizer.
The CEOs of Bristol Myers Squibb, Johnson & Johnson and Merck testified Thursday before the Senate health committee, defending the high U.S. prices that Americans pay for prescription drugs compared to other countries based on patient value and the need to fund innovation and R&D costs.
Neurona Therapeutics on Thursday announced that it has secured $120 million in funding, which will help it advance its pipeline of investigational off-the-shelf cell therapies.
ReutersRoche is cutting 345 jobs, Swiss website Muula reported, as the drugs company responds to lower profit posted for 2023 and a more cautious outlook for the year ahead.
BioNTech is making moves in early 2024 to strengthen its CAR T pipeline, with a $250 million licensing and manufacturing deal announced Thursday with Autolus Therapeutics to advance the companies’ respective programs.
The European Medicines Agency is investigating the potential impacts that Novo Holdings’ $16.5 billion acquisition of contract manufacturing giant Catalent will have on drug supply, according to reporting Wednesday by Reuters.
AstraZeneca on Thursday released its fourth-quarter and full-year financial results, touting 6% total revenue growth for 2023 even as its COVID-19 business plummeted by more than 90%.
Kyverna Therapeutics will debut on the Nasdaq Global Select Market under the ticker symbol KYTX after announcing that it is putting up for sale 14.5 million shares of its common stock for $22 apiece in an upsized initial public offering.
Eli Lilly agreed to provide low-cost insulin to patients and donate free insulin to clinics, to settle a lawsuit by Minnesota that accused the three largest insulin makers of deceptively raising the price of the diabetes treatment.
